| Title: |
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection |
| Authors: |
Ferrari, Ludovica; Ruggiero, Alessandra; Stefani, Chiara; Benedetti, Livia; Piermatteo, Lorenzo; Andreassi, Eleonora; Caldara, Federica; Zace, Drieda; Pagliari, Matteo; Ceccherini-Silberstein, Francesca; Jones, Christopher; Iannetta, Marco; Geretti, Anna Maria; Ansaldo, Lorenzo; Bertoli, Ada; Bonfante, Francesco; Braccialarghe, Neva; Checchi, Davide; Compagno, Mirko; De Simone, Giuseppe; Grelli, Sandro; Meloni, Diletta; Mulas, Tiziana; Sarmati, Loredana; Teti, Elisabetta; null, null |
| Contributors: |
Ferrari, Ludovica; Ruggiero, Alessandra; Stefani, Chiara; Benedetti, Livia; Piermatteo, Lorenzo; Andreassi, Eleonora; Caldara, Federica; Zace, Drieda; Pagliari, Matteo; Ceccherini-Silberstein, Francesca; Jones, Christopher; Iannetta, Marco; Geretti, Anna Maria; Ansaldo, Lorenzo; Bertoli, Ada; Bonfante, Francesco; Braccialarghe, Neva; Checchi, Davide; Compagno, Mirko; De Simone, Giuseppe; Grelli, Sandro; Meloni, Diletta; Mulas, Tiziana; Sarmati, Loredana; Teti, Elisabetta; Null, Null |
| Publication Year: |
2024 |
| Collection: |
Padua Research Archive (IRIS - Università degli Studi di Padova) |
| Description: |
Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38594459; info:eu-repo/semantics/altIdentifier/wos/WOS:001199822700075; volume:14; issue:1; firstpage:8337; journal:SCIENTIFIC REPORTS; https://hdl.handle.net/11577/3512676 |
| DOI: |
10.1038/s41598-024-58597-4 |
| Availability: |
https://hdl.handle.net/11577/3512676; https://doi.org/10.1038/s41598-024-58597-4 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.66188677 |
| Database: |
BASE |